Literature DB >> 23216230

Hemotherapy bedside biovigilance involving vital sign values and characteristics of patients with suspected transfusion reactions associated with fluid challenges: can some cases of transfusion-associated circulatory overload have proinflammatory aspects?

Chester Andrzejewski1, Mark A Popovsky, Theresa C Stec, Jean Provencher, Lynne O'Hearn, Paul Visintainer, Jay Steingrub.   

Abstract

BACKGROUND: Monitoring of patients' vital sign values (VSVs) during hemotherapy may have an important role in the recognition and mitigation of transfusion-associated circulatory overload (TACO). Knowledge regarding VSVs and other patient characteristics in bedside-reported TACO or fluid challenge-suspected transfusion reactions (TACO/FC-STRs) is limited. STUDY DESIGN AND METHODS: We performed a retrospective observational cohort study of cases of uncomplicated red blood cell (RBC) transfusions (UCTs) and reported suspected transfusion reaction (STR) cases investigated by our hospital's transfusion medicine service (TMS) from January 1, 2005, to February 29, 2008, using data obtained from TMS consult reports and quality improvement databases examining VSVs and patient characteristics in TACO/FC-STRs.
RESULTS: The frequency of TACO/FC-STRs was 0.19% per all RBC units transfused (1:530 units transfused). Both clinically and statistically (p≤0.05) significant changes were encountered in all VSVs in patients experiencing TACO/FC-STRs either at the 15-minute time interval or at the end-of-transfusion time points. Measured and derived VSVs related to the patients' blood pressure in the peritransfusion period were consistently increased. Approximately two-thirds of TACO/FC-STR patients also exhibited inflammatory related signs and symptoms at STR bedside presentation. Differences (all p≤0.050) between UCT and TACO/FC-STR cohorts were seen for patient mean weights (80 kg vs. 72 kg), mean minutes to transfusion completion (121 min vs. 83 min), and mean storage age of suspected sentinel RBC unit (22.5 days vs. 25.2 days).
CONCLUSION: Trend monitoring of peritransfusion VSVs, especially blood pressures, may aid in the bedside recognition of TACO/FC-STRs. A subset of these patients may also present with febrile and/or inflammatory signs and symptoms.
© 2012 American Association of Blood Banks.

Entities:  

Mesh:

Year:  2012        PMID: 23216230     DOI: 10.1111/j.1537-2995.2012.03595.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  11 in total

1.  Transfusion-associated circulatory overload in adult, medical emergency patients with perspectives on early warning practice: a single-centre, clinical study.

Authors:  Fanny Gosmann; Astrid Nørgaard; Maj-Britt Rasmussen; Charlotte Rahbek; Jens Seeberg; Tom Møller
Journal:  Blood Transfus       Date:  2017-01-26       Impact factor: 3.443

2.  A multicentre study investigating vital sign changes occurring in complicated and uncomplicated transfusions.

Authors:  E A Gehrie; N H Roubinian; D Chowdhury; D J Brambilla; E L Murphy; J L Gottschall; Y Wu; P M Ness; R G Strauss; J E Hendrickson
Journal:  Vox Sang       Date:  2017-12-25       Impact factor: 2.144

3.  Incidence and clinical characteristics of transfusion-associated circulatory overload using an active surveillance algorithm.

Authors:  N H Roubinian; J E Hendrickson; D J Triulzi; J L Gottschall; D Chowdhury; D J Kor; M R Looney; M A Matthay; S H Kleinman; D Brambilla; E L Murphy
Journal:  Vox Sang       Date:  2016-12-21       Impact factor: 2.144

4.  Risk Factors and Clinical Outcomes Associated with Perioperative Transfusion-associated Circulatory Overload.

Authors:  Leanne Clifford; Qing Jia; Arun Subramanian; Hemang Yadav; Darrell R Schroeder; Daryl J Kor
Journal:  Anesthesiology       Date:  2017-03       Impact factor: 7.892

5.  Prophylactic furosemide to prevent transfusion-associated circulatory overload: a randomized controlled study in rats.

Authors:  Robert B Klanderman; Joachim J Bosboom; Denise P Veelo; Joris J T H Roelofs; Dirk de Korte; Robin van Bruggen; Liffert Vogt; Jaap D van Buul; Markus W Hollmann; Margreeth B Vroom; Nicole P Juffermans; Bart F Geerts; Alexander P J Vlaar
Journal:  Sci Rep       Date:  2022-07-15       Impact factor: 4.996

6.  Point-of-care washing of allogeneic red blood cells for the prevention of transfusion-related respiratory complications (WAR-PRC): a protocol for a multicenter randomised clinical trial in patients undergoing cardiac surgery.

Authors:  Matthew A Warner; Ian J Welsby; Phillip J Norris; Christopher C Silliman; Sarah Armour; Erica D Wittwer; Paula J Santrach; Laurie A Meade; Lavonne M Liedl; Chelsea M Nieuwenkamp; Brian Douthit; Camille M van Buskirk; Phillip J Schulte; Rickey E Carter; Daryl J Kor
Journal:  BMJ Open       Date:  2017-08-18       Impact factor: 2.692

7.  Haemovigilance of reactions associated with red blood cell transfusion: comparison across 17 Countries.

Authors:  M A M Rogers; J M Rohde; N Blumberg
Journal:  Vox Sang       Date:  2015-12-21       Impact factor: 2.144

8.  Volume incompliance and transfusion are essential for transfusion-associated circulatory overload: a novel animal model.

Authors:  Robert B Klanderman; Joachim J Bosboom; Adrie A W Maas; Joris J T H Roelofs; Dirk de Korte; Robin van Bruggen; Jaap D van Buul; Coert J Zuurbier; Denise P Veelo; Markus W Hollmann; Margreeth B Vroom; Nicole P Juffermans; Bart F Geerts; Alexander P J Vlaar
Journal:  Transfusion       Date:  2019-11-07       Impact factor: 3.157

9.  Remote Patient Monitoring in Adults Receiving Transfusion or Infusion for Hematological Disorders Using the VitalPatch and accelerateIQ Monitoring System: Quantitative Feasibility Study.

Authors:  Rik Paulus Bernardus Tonino; Karen Larimer; Okke Eissen; Martin Roelof Schipperus
Journal:  JMIR Hum Factors       Date:  2019-12-02

10.  Associated Factors With Acute Transfusion Reaction From Hospital Online Reporting Events: A Retrospective Cohort Study.

Authors:  Chao-Yuan Yao; Ju-Huei Chien; Hsun-Yang Chuang; Tsing-Fen Ho
Journal:  J Patient Saf       Date:  2020-12       Impact factor: 2.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.